Financial Express (Holdings) Limited (“we”, “our”, “us” and derivatives) are committed to protecting and respecting your privacy. This Privacy Policy, together with our Terms of Use, sets out the basis on which any personal data that we collect from you, or that you provide to us, will be processed by us relating to your use of any of the below websites (“sites”).


For the purposes of the Data Protection Act 1998, the data controller is Trustnet Limited of 2nd Floor, Golden House, 30 Great Pulteney Street, London, W1F 9NN. Our nominated representative for the purpose of this Act is Kirsty Witter.


We collect information about you when you register with us or use any of our websites / services. Part of the registration process may include entering personal details & details of your investments.

We may collect information about your computer, including where available your operating system, browser version, domain name and IP address and details of the website that you came from, in order to improve this site.

You confirm that all information you supply is accurate.


In order to provide personalised services to and analyse site traffic, we may use a cookie file which is stored on your browser or the hard drive of your computer. Some of the cookies we use are essential for the sites to operate and may be used to deliver you different content, depending on the type of investor you are.

You can block cookies by activating the setting on your browser which allows you to refuse the setting of all or some cookies. However, if you use your browser settings to block all cookies (including essential cookies) you may not be able to access all or part of our sites. Unless you have adjusted your browser setting so that it will refuse cookies, our system will issue cookies as soon as you visit our sites.


We store and use information you provide as follows:

  • to present content effectively;
  • to provide you with information, products or services that you request from us or which may interest you, tailored to your specific interests, where you have consented to be contacted for such purposes;
  • to carry out our obligations arising from any contracts between you and us;
  • to enable you to participate in interactive features of our service, when you choose to do so;
  • to notify you about changes to our service;
  • to improve our content by tracking group information that describes the habits, usage, patterns and demographics of our customers.

We may also send you emails to provide information and keep you up to date with developments on our sites. It is our policy to have instructions on how to unsubscribe so that you will not receive any future e-mails. You can change your e-mail address at any time.

In order to provide support on the usage of our tools, our support team need access to all information provided in relation to the tool.

We will not disclose your name, email address or postal address or any data that could identify you to any third party without first receiving your permission.

However, you agree that we may disclose to any regulatory authority to which we are subject and to any investment exchange on which we may deal or to its related clearing house (or to investigators, inspectors or agents appointed by them), or to any person empowered to require such information by or under any legal enactment, any information they may request or require relating to you, or if relevant, any of your clients.

You agree that we may pass on information obtained under Money Laundering legislation as we consider necessary to comply with reporting requirements under such legislation.


We want to ensure that the personal information we hold about you is accurate and up to date. You may ask us to correct or remove information that is inaccurate.

You have the right under data protection legislation to access information held about you. If you wish to receive a copy of any personal information we hold, please write to us at 3rd Floor, Hollywood House, Church Street East, Woking, GU21 6HJ. Any access request may be subject to a fee of £10 to meet our costs in providing you with details of the information we hold about you.


The data that we collect from you may be transferred to, and stored at, a destination outside the European Economic Area (“EEA”). It may be processed by staff operating outside the EEA who work for us or for one of our suppliers. Such staff may be engaged in, amongst other things, the provision of support services. By submitting your personal data, you agree to this transfer, storing and processing. We will take all steps reasonably necessary, including the use of encryption, to ensure that your data is treated securely and in accordance with this privacy policy.

Unfortunately, the transmission of information via the internet is not completely secure. Although we will do our best to protect your personal data, we cannot guarantee the security of your data transmitted to our sites; any transmission is at your own risk. You will not hold us responsible for any breach of security unless we have been negligent or in wilful default.


Any changes we make to our privacy policy in the future will be posted on this page and, where appropriate, notified to you by e-mail.


Our sites contain links to other websites. If you follow a link to any of these websites, please note that these websites have their own privacy policies and that we do not accept any responsibility or liability for these policies. Please check these policies before you submit any personal data to these websites.


If you want more information or have any questions or comments relating to our privacy policy please email [email protected] in the first instance.

 Information  X 
Enter a valid email address

XTL Biopharm Ltd (XTL)

  Print      Mail a friend

Thursday 18 November, 2004

XTL Biopharm Ltd

Progress in HepeX-C Program

XTL Biopharmaceuticals Ltd
18 November 2004

XTL Biopharmaceuticals Ltd Reports Progress in HepeX-C Program

Rehovot, Israel, 18 November 2004: XTL Biopharmaceuticals Ltd. (LSE: XTL)
('XTLbio' or the 'Company') reports progress in developing HepeX-C as a
combination of two human monoclonal antibodies (MAb's) for prevention of
re-infection with HCV following liver transplantation (LT):

    * FDA formally releases clinical hold on Phase 2a trial with single MAb
      (AbXTL68) product;
    * Following analysis of results available from the above trial, XTLbio can 
      now estimate target dosing regimen range required to achieve a therapeutic 
      effect in LT patients without the need to continue this trial; and
    * Following a positive Pre-IND meeting with FDA, XTLbio to file an IND for
      HepeX-C as a dual MAb product in the first half of 2005.

The Company has received notification from the FDA that the phase 2a trial with
AbXTL68 is formally off clinical hold. XTLbio has now completed analysis of the
first 5 cohorts of this trial. This analysis has enabled XTLbio to estimate the
target dosing regimen required for a therapeutic effect in liver transplant
patients and therefore no further patient recruitment is necessary. This
information has already been incorporated in the design of upcoming studies with

The first part of HepeX-C's development strategy was evaluation of a single
antibody (AbXTL68) in patients with chronic HCV and in liver transplant
patients. These 2 trials have evaluated safety, antiviral and pharmacokinetic
properties of AbXTL68 and have allowed the Company to estimate the target dose /
frequency range required for a therapeutic effect in liver transplant patients.
This information is critical for the design of the second part of HepeX-C's
development strategy - evaluation of the dual-MAb product in clinical trials.

Based on this the Company had a pre-IND meeting with the FDA at which XTLbio
presented data on AbXTL68 and AbXTL65 which has just successfully completed
pre-clinical development. XTLbio also presented the rationale for developing
HepeX-C as a combination product containing AbXTL68 and AbXTL65 (targeting
different viral sites). Similar drug combination approaches are currently
employed in treatment of other viral diseases. XTLbio's HepeX-B, currently in
Phase 2b for preventing re-infection with HBV in liver transplant patients, is
also a dual-MAb product.

The clinical trial design discussed with FDA includes a dose escalating study
with HepeX-C in patients with chronic HCV to evaluate safety and biological
activity of the drug. This study will be followed by a trial in liver transplant
patients. XTLbio is now preparing an IND for the dual-MAb product for submission
to the FDA in the first half of 2005.

'The studies we have conducted to date with AbXTL68 as a single agent provided
us with preliminary indication of safety and antiviral activity of AbXTL68, and
enabled us to estimate the target therapeutic dose / frequency range in liver
transplant patients. We are now applying the information gathered in these
trials to the development of HepeX-C as a dual-antibody product. We are excited
to move forward rapidly with the development of HepeX-C' said Dr. Neil Graham,
XTLbio's Chief Medical Officer.


Dr. Neil Graham, Chief Medical Officer              Tel: +1 919 806 4623

About XTLbio

XTL Biopharmaceuticals Ltd. (XTLbio) is a biopharmaceutical company developing
drugs against hepatitis. XTLbio's HepeXTM product line - now in clinical trials
- has the potential to introduce revolutionary therapies for viral hepatitis,
including prevention of re-infection in transplanted livers, the Company's
primary focus, and a longer-term cocktail approach in treating chronic illness.
XTLbio believes its primary competitive advantage lies in its patented TrimeraTM
technology, which enables the development of fully human monoclonal antibodies
and models of human disease for pre-clinical drug validation. Established in
1993, XTLbio became a public company in 2000 and its shares are listed on the
Official List of the UK Listing Authority and are traded on the London Stock
Exchange under the symbol XTL.

About hepatitis C
Hepatitis C is a major public health concern. The World Health Organization
estimates that 170 million people worldwide are chronic carriers of the
hepatitis C virus (HCV) and that 3 to 4 million people are newly infected each
year. It is expected that 25 to 35% of these chronic patients will develop
progressive liver disease including cirrhosis and liver cancer. Hepatitis C is
the single leading cause of liver transplantation. The US Centres for Disease
Control and Prevention estimate that approximately 4 million people in the
United States (almost 2% of the population) have been infected with HCV, of
whom, approximately 3 million are chronically ill. Hepatitis C is the cause of
an estimated 8,000 to 10,000 deaths annually in the US.

About HCV-related liver transplant prophylaxis
Approximately 5% of chronic HCV patients will develop end-stage liver disease,
and ultimately may require liver transplantation. Today, there is a major
problem associated with HCV-related liver transplantation. Although the infected
liver - the major source of viral replication - has been removed, free-floating
virus in the patient's serum re-infects the healthy transplanted liver in a
matter of weeks. Disease progression in re-infected patients is several times
faster and, in many cases, a re-transplant becomes necessary. At present, there
is no available solution to this problem.

HepeXTM, TrimeraTM, XTLTM and XTLbioTM are trademarks of XTL Biopharmaceuticals

                      This information is provided by RNS
            The company news service from the London Stock Exchange

a d v e r t i s e m e n t